Expression patterns and clinical implications of chaperonin subunit 3 mRNA and protein in laryngeal squamous cell carcinoma

Table 1 The relationship between chaperonin-containing TCP1 subunit 3 protein expression and clinical characteristics in patients with laryngeal squamous cell carcinoma from the in-house immunohistochemistry dataset

Clinical features	CCT3 protein expression			t or F (ANOVA test)	P value
	Number	Mean	SD
Age				0.538	0.5951
> 55	12	9.500	1.698
≤ 55	18	9.822	1.548
Sex				0.448	0.6573
Male	28	9.729	1.608
Female	2	9.200	1.697
Clinical stage				0.537	0.7097
Stage I	12	9.533	1.533
Stage II	8	9.900	1.720
Stage III	4	8.900	1.800
Stage I-II	2	9.800	0.0283
Stage II-III	4	10.050	1.915
TNM-N
N1	24	9.683	1.565	-0.678	0.9465
N2	6	9.733	1.836
TNM-T				2.533	0.0982
T1	2	9.800	1.979
T2	26	9.508	1.519
T3	2	12.000	0.000

CCT3: Chaperonin-containing TCP1 subunit 3; ANOVA: Analysis of variance; TNM-N: Tumor node metastasis-node; TNM-T: Tumor node metastasis-tumor.